Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it intends to release on Thursday, 22 November 2012 its financial results for the six months ended 30 September 2012. The release will be issued shortly after 9:00am NZDT, 7:00am AEDT (3:00pm USEST, Wednesday 21 November).
Fisher & Paykel Healthcare will host a conference call on Thursday, 22 November 2012 to review the results and to discuss the outlook for the remainder of the 2013 financial year. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT (4:00pm USEST, Wednesday, 21 November) and will be broadcast simultaneously over the Internet.
To listen to the webcast, access the company’s website at www.fphcare.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software if required. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.
To attend the conference call, participants will need to dial in to one of the numbers below at least 5 minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: 64309591
New Zealand Toll Free 0800 452 569
USA Toll Free 1866 242 1388
Australia Toll Free 1800 354 715
Hong Kong Toll Free 800 968 831
United Kingdom Toll Free 0808 234 7860
International +61 2 8823 6760
An audio replay of the conference call will be available approximately 2 hours after the call and will be accessible for two weeks by dialing one of the numbers below. When prompted please enter the conference code of: 64309591.
New Zealand Toll Free 0800 453 213
USA Toll Free 1855 452 5696
Australia Toll Free 1800 153 898
Hong Kong Toll Free 800 963 117
United Kingdom Toll Free 0808 234 0072
International +61 2 8199 0299
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119.
Half Year Results to be announced on 22 November 2012
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment